These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22537450)

  • 1. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.
    Agai-Csongor E; Domány G; Nógrádi K; Galambos J; Vágó I; Keserű GM; Greiner I; Laszlovszky I; Gere A; Schmidt E; Kiss B; Vastag M; Tihanyi K; Sághy K; Laszy J; Gyertyán I; Zájer-Balázs M; Gémesi L; Kapás M; Szombathelyi Z
    Bioorg Med Chem Lett; 2012 May; 22(10):3437-40. PubMed ID: 22537450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
    Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
    Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.
    Tóth M; Varrone A; Steiger C; Laszlovszky I; Horváth A; Kiss B; Gyertyán I; Adham N; Halldin C; Gulyás B
    Synapse; 2013 May; 67(5):258-64. PubMed ID: 23238770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].
    Sumegi A; Varga E
    Neuropsychopharmacol Hung; 2010 Sep; 12(3):405-11. PubMed ID: 20962360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
    J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder.
    Johnson DS; Choi C; Fay LK; Favor DA; Repine JT; White AD; Akunne HC; Fitzgerald L; Nicholls K; Snyder BJ; Whetzel SZ; Zhang L; Serpa KA
    Bioorg Med Chem Lett; 2011 May; 21(9):2621-5. PubMed ID: 21353774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
    Kesten SR; Heffner TG; Johnson SJ; Pugsley TA; Wright JL; Wise LD
    J Med Chem; 1999 Sep; 42(18):3718-25. PubMed ID: 10479303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
    Choi YK; Adham N; Kiss B; Gyertyán I; Tarazi FI
    CNS Spectr; 2017 Dec; 22(6):484-494. PubMed ID: 28059046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Aug; 40(17):2688-93. PubMed ID: 9276014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
    Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
    Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.